Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

10.11
-0.0900-0.88%
Post-market: 10.110.00000.00%16:05 EDT
Volume:565.68K
Turnover:5.69M
Market Cap:466.01M
PE:-3.42
High:10.22
Open:10.20
Low:9.97
Close:10.20
Loading ...

UroGen Pharma Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General Dynamics

Reuters
·
17 Apr

UroGen Pharma Initiated at Sector Outperform by Scotiabank

Dow Jones
·
16 Apr

Scotiabank Initiates UroGen Pharma at Sector Outperform With $23 Price Target

MT Newswires Live
·
16 Apr

Urogen Pharma Ltd : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $23

THOMSON REUTERS
·
16 Apr

High Growth Tech Stocks In The US To Watch April 2025

Simply Wall St.
·
09 Apr

UroGen Pharma price target lowered to $55 from $64 at H.C. Wainwright

TIPRANKS
·
11 Mar

Analysts Offer Insights on Healthcare Companies: Inozyme Pharma (INZY) and Urogen Pharma (URGN)

TIPRANKS
·
11 Mar

Urogen Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
10 Mar

Urogen Pharma reports wider-than-expected fourth-quarter loss

Reuters
·
10 Mar

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
10 Mar

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
10 Mar

UroGen Pharma Q4 2024 GAAP EPS $(0.80) Misses $(0.68) Estimate, Sales $24.57M Miss $25.63M Estimate

Benzinga
·
10 Mar

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Business Wire
·
10 Mar

Exploring High Growth Tech Stocks in the US Market

Simply Wall St.
·
08 Mar

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
07 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Press Release: UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

Dow Jones
·
27 Feb

UroGen Pharma Price Target Maintained With a $64.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

UroGen Pharma Coverage Assumed by Ladenburg Thalmann at Buy

Dow Jones
·
20 Feb